MedImmune’s Mott heads for the exit; Italian regulators suspended in scandal;

> David Mott, the CEO of MedImmune who led his company through a $15.6 billion buyout by AstraZeneca, is leaving the company a year after the deal closed. Report

> The director of Italy's medicines regulatory agency has been suspended along with another top official, as the drug licences-for-cash scandal surrounding the organisation continues to unfold. Report

> Fresh from losing an insurgent attack aimed at winning back control of Biovail, Canadian entrepreneur Eugene Melnyk says he plans to invest $50 million to $100 million of his own money to start a new R&D focused development company--Trimel Pharmaceuticals. Report

> A South Korean patent court ruled in favour of five local pharmaceutical companies involved in a Lipitor patent dispute with Pfizer. Report

> Bayer won a court ruling that an Abbott Laboratories patent covering glucose-testing products isn’t enforceable, because Abbott's lawyer used deception to get the patent in the first place. Report

> Bristol-Myers Squibb wrapped up its tender offer for Kosan Biosciences. Report

> Daiichi Sankyo has decided to buy back a maximum of 15 million, or about 2 percent, of the company's outstanding ordinary shares for a total acquisition price of up to 50 billion yen. Report

> AstraZeneca refused to rule out a possible relocation of its headquarters to reduce the impact of taxes paid to the UK. Report

> Belgian healthcare group UCB expects to launch its new epilepsy drug Vimpat early in the fourth quarter, pending final European approval. Report

> Sinclair Pharma signed its first marketing distribution agreement in India with Wockhardt for a range of its oral and dermatology products. Release

> After a two-year run, pharmaceutical giant Wyeth is parting ways with Publicis Groupe's Kaplan Thaler Group, placing creative duties on the $55 million marketing account for its Centrum brand into review. Report

> Ruti Alon, general partner of Pitango Venture Capital, says the Israeli government will need to invest a significant amount of capital in its biotech industry if the industry intends to achieve its full potential in the field. Report

> Arizona officials have always talked an ambitious game plan for fostering its fledgling biotech sector. Now a biotechnology incubator and life sciences association in Arizona has launched the ThirdBiotech Research Group. Report

And Finally... Merck and Schering-Plough are ending their respiratory joint venture and their eight-year effort to market a combination of their Claritin and Singulair medications, which are used to treat allergic rhinitis. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.